Evidence map›Paper›PMID 32052165›Full record

ArticleJournal of neurology2020

Prognostic role of slow vital capacity in amyotrophic lateral sclerosis.

Andrea Calvo, Rosario Vasta, Cristina Moglia, Enrico Matteoni, Antonio Canosa, Alessio Mattei, Claudio La Mancusa, Luana Focaraccio, Letizia Mazzini, Adriano Chiò and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Andrea Calvo *Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy. andrea.calvo@unito.it.ORCID http://orcid.org/0000-0002-5122-7243
Rosario Vasta *Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Cristina MogliaDepartment of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Enrico MatteoniDepartment of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Antonio CanosaDepartment of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Alessio MatteiSC Pneumologia, AOU Città della Salute e della Scienza of Turin, Turin, Italy.
Claudio La MancusaDepartment of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Luana FocaraccioPresidio ASL4, Pneumologia, Turin, Lanzo Torinese, Italy.
Letizia MazziniALS Center, Ospedale Maggiore della Carità, Novara, Italy.
Adriano ChiòDepartment of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Fabrizio D'Ovidio *Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
Umberto Manera *Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITPresidio Ospedaliero · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the prognostic role of FVC and SVC at diagnosis in amyotrophic lateral sclerosis (ALS) patients.

methodsWe included all patients from the Piemonte and Valle D'Aosta ALS register (PARALS) who had been diagnosed with ALS between 1995 and 2015 and underwent spirometry at diagnosis. Survival was considered as time to death/tracheostomy; to assess the prognostic value in typical trial timeframes, survival at 12 and 18 months was calculated too. Cox proportional hazard regression models adjusted by sex, age at diagnosis, diagnostic delay, onset site, and ALSFRS-R total score at the moment of diagnosis were used to assess the prognostic role of FVC and SVC.

resultsA total of 795 ALS patients underwent spirometry at diagnosis during the study period. Four hundred and sixteen (52.3%) performed both FVC and SVC, whereas the others performed FVC only. FVC and SVC values were highly correlated (r = 0.92, p < 0.001) in the overall population and slightly less correlated in patients with bulbar onset (r = 0.86, p < 0.001). Both FVC and SVC proved to have a prognostic role with comparable hazard ratios (HRs) (HR 1.83, 95% CI 1.48-2.27 and 1.88, 95% CI 1.51-2.33, respectively). When considering typical trial timeframes, HRs remained similar and were inversely proportional to FVC and SVC values. DISCUSSION: FVC and SVC at diagnosis can be used interchangeably as independent predictors of survival in both clinical and research settings.

Indexed as

RegistriesAgedAmyotrophic Lateral SclerosisFemaleHumansMaleMiddle AgedPrognosisSpirometryVital CapacityAmyotrophic lateral sclerosisCohort studiesEpidemiologySlow vital capacity

Identifiers

PMID32052165
OpenAlexW3006411949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.